| Matthew F Lee, MD | |
|
150 Duncan Rd, Buckeye, WV 24924-9037 | |
| (304) 799-7400 | |
| (304) 799-2276 |
| Full Name | Matthew F Lee |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 150 Duncan Rd, Buckeye, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407964570 | NPI | - | NPPES |
| 930108513 | Other | KY | RAILROAD |
| 64037450 | Medicaid | KY | |
| 1407694570 | Other | WV | BLUE SHIELD |
| 2000559000 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20541 (West Virginia) | Secondary |
| 207P00000X | Emergency Medicine | 36847 (Kentucky) | Primary |
| Entity Name | Pocahontas Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609842251 PECOS PAC ID: 9234100645 Enrollment ID: O20041018000008 |
News Archive
Ascension Orthopedics, Inc., the world leader in PyroCarbon orthopedic devices, announces the implantation of the first PyroTITAN™ Humeral Resurfacing Implant in the United Kingdom. The PyroTITAN was implanted at BMI - The Alexandra Hospital in Cheadle, Cheshire.
A new way of producing an enzyme called fucosyltransferase VI (FTVI) in the lab could help enhance the therapeutic potential of cord blood transplants.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.
Dr. Fred Gage, a professor in the Salk Institute Laboratory of Genetics and holder of the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases, has been named a 2011 recipient of the prestigious National Institutes of Health (NIH) Director's Transformative Research Projects (T-R01) program.
› Verified 7 days ago
| Entity Name | Health Care Alliance, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730128760 PECOS PAC ID: 5799689105 Enrollment ID: O20050816000292 |
News Archive
Ascension Orthopedics, Inc., the world leader in PyroCarbon orthopedic devices, announces the implantation of the first PyroTITAN™ Humeral Resurfacing Implant in the United Kingdom. The PyroTITAN was implanted at BMI - The Alexandra Hospital in Cheadle, Cheshire.
A new way of producing an enzyme called fucosyltransferase VI (FTVI) in the lab could help enhance the therapeutic potential of cord blood transplants.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.
Dr. Fred Gage, a professor in the Salk Institute Laboratory of Genetics and holder of the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases, has been named a 2011 recipient of the prestigious National Institutes of Health (NIH) Director's Transformative Research Projects (T-R01) program.
› Verified 7 days ago
| Entity Name | Oak Hill Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891075057 PECOS PAC ID: 8123292950 Enrollment ID: O20111114000227 |
News Archive
Ascension Orthopedics, Inc., the world leader in PyroCarbon orthopedic devices, announces the implantation of the first PyroTITAN™ Humeral Resurfacing Implant in the United Kingdom. The PyroTITAN was implanted at BMI - The Alexandra Hospital in Cheadle, Cheshire.
A new way of producing an enzyme called fucosyltransferase VI (FTVI) in the lab could help enhance the therapeutic potential of cord blood transplants.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.
Dr. Fred Gage, a professor in the Salk Institute Laboratory of Genetics and holder of the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases, has been named a 2011 recipient of the prestigious National Institutes of Health (NIH) Director's Transformative Research Projects (T-R01) program.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew F Lee, MD 150 Duncan Rd, Buckeye, WV 24924-9037 Ph: (304) 799-7400 | Matthew F Lee, MD 150 Duncan Rd, Buckeye, WV 24924-9037 Ph: (304) 799-7400 |
News Archive
Ascension Orthopedics, Inc., the world leader in PyroCarbon orthopedic devices, announces the implantation of the first PyroTITAN™ Humeral Resurfacing Implant in the United Kingdom. The PyroTITAN was implanted at BMI - The Alexandra Hospital in Cheadle, Cheshire.
A new way of producing an enzyme called fucosyltransferase VI (FTVI) in the lab could help enhance the therapeutic potential of cord blood transplants.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.
Dr. Fred Gage, a professor in the Salk Institute Laboratory of Genetics and holder of the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases, has been named a 2011 recipient of the prestigious National Institutes of Health (NIH) Director's Transformative Research Projects (T-R01) program.
› Verified 7 days ago